Therapeutic Advances in Cardiac Myosin Modulation

Abstract

Cardiac myosin modulators represent a transformative approach in the management of various forms of heart failure, particularly in patients with hypertrophic and dilated cardiomyopathies. Recent advancements have elucidated the role of myosin as a pivotal target for pharmacological intervention, enabling direct modulation of cardiac contractility at the molecular level. This review synthesizes current evidence on the epidemiology, pathophysiology, clinical features, diagnostic strategies, and therapeutic paradigms involving myosin modulation, with particular emphasis on emerging agents such as mavacamten and omecamtiv mecarbil. We discuss the mechanistic rationale, clinical trial data, and guideline implications for these novel therapies, providing a comprehensive, evidence-based resource for clinicians and researchers.

Introduction

The landscape of heart failure management is rapidly evolving, driven by a deeper understanding of molecular mechanisms underlying contractile dysfunction. Therapeutics targeting the sarcomere, specifically cardiac myosin, have emerged as promising interventions for conditions characterized by either hypercontractility or contractile insufficiency. Cardiac myosin modulators can either inhibit or activate myosin ATPase activity, allowing for tailored intervention in disorders such as hypertrophic cardiomyopathy (HCM) and heart failure with reduced ejection fraction (HFrEF). This article provides an in-depth review of cardiac myosin modulation, examining its scientific foundation, clinical relevance, and therapeutic potential.

Epidemiology / Disease Burden

Heart failure continues to pose a substantial global health burden, affecting over 64 million individuals worldwide. Hypertrophic cardiomyopathy, the most prevalent inherited cardiac disease, affects approximately 1 in 500 individuals, whereas dilated cardiomyopathy is a leading cause of heart transplantation. Both conditions contribute significantly to morbidity, mortality, and healthcare costs. Despite advances in conventional therapies, a significant proportion of patients with systolic or diastolic dysfunction remain symptomatic, underscoring the need for novel, mechanism-driven treatments such as myosin modulators.

Pathophysiology

Cardiac myosin, a motor protein within the sarcomere, plays a central role in generating force and contractility during the cardiac cycle. In HCM, pathogenic mutations often enhance myosin-actin interactions, leading to hypercontractility, diastolic dysfunction, and myocardial hypertrophy. Conversely, in HFrEF, impaired myosin function results in reduced contractile force and systolic dysfunction. Therapeutic modulation of myosin can rectify these abnormalities: inhibitors such as mavacamten decrease excessive cross-bridge cycling in HCM, while activators like omecamtiv mecarbil enhance contractile performance in systolic heart failure without increasing myocardial oxygen demand.

Risk Factors

Genetic predispositions are primary risk factors for cardiomyopathies amenable to myosin modulation. Mutations in sarcomeric proteins, particularly MYH7 and MYBPC3, underlie the majority of HCM cases. Additional risk factors include hypertension, metabolic syndrome, exposure to cardiotoxic agents, and certain viral infections, which may precipitate or exacerbate underlying myocardial dysfunction. Understanding these risk factors is crucial for patient selection and optimizing therapeutic outcomes with myosin modulators.

Clinical Features

Patients with HCM commonly present with exertional dyspnea, chest pain, palpitations, or syncope, often in the context of preserved ejection fraction but impaired diastolic filling. In contrast, HFrEF manifests as fatigue, reduced exercise capacity, pulmonary congestion, and peripheral edema. Both conditions carry a risk of arrhythmias and sudden cardiac death. Early identification of clinical phenotypes is essential to guide appropriate diagnostic workup and initiate targeted therapies, including myosin modulators where indicated.

Diagnosis

Diagnostic evaluation involves a combination of clinical assessment, imaging, and genetic testing. Echocardiography remains the cornerstone for assessing ventricular morphology, wall thickness, and systolic function. Cardiac magnetic resonance imaging provides detailed tissue characterization, while genetic testing identifies pathogenic variants in sarcomeric genes. Biomarkers such as NT-proBNP aid in risk stratification and monitoring therapeutic response. Accurate diagnosis is imperative for identifying candidates for myosin modulation and monitoring disease progression.

Treatment & Management

Traditional management of HCM includes beta-blockers, calcium channel blockers, and disopyramide to alleviate symptoms and reduce outflow tract gradients. In advanced cases, septal reduction therapies or implantable cardioverter-defibrillators may be indicated. For HFrEF, guideline-directed medical therapy encompasses ACE inhibitors, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors. However, these regimens do not directly address sarcomeric dysfunction. Myosin modulators offer a novel approach by directly targeting the contractile apparatus, providing symptomatic relief and potentially modifying disease trajectory.

Recent Advances / Emerging Therapies

Mavacamten, a selective myosin inhibitor, has demonstrated significant efficacy in reducing left ventricular outflow tract gradients and improving symptoms in obstructive HCM, as evidenced by the EXPLORER-HCM and VALOR-HCM trials. Omecamtiv mecarbil, a cardiac myosin activator, has shown promise in improving systolic function and clinical outcomes in HFrEF populations, as seen in the GALACTIC-HF trial. Both agents have favorable safety profiles, with careful titration required to avoid excessive contractility modulation. Ongoing studies are evaluating next-generation myosin modulators and their role in broader patient populations, including non-obstructive HCM and heart failure with preserved ejection fraction (HFpEF).

Guideline Recommendations

Recent updates from the American College of Cardiology and the European Society of Cardiology incorporate myosin modulators as potential therapeutic options for symptomatic obstructive HCM refractory to conventional therapy. These agents are recommended under specialist supervision, with close monitoring of contractile function. For HFrEF, myosin activators are under active investigation, with anticipated guideline incorporation pending results from ongoing phase III trials. Clinicians should remain current with evolving recommendations to optimize patient outcomes.

Conclusion

Cardiac myosin modulation has redefined the therapeutic landscape for cardiomyopathies, offering targeted, mechanism-based intervention for previously intractable conditions. The integration of myosin inhibitors and activators into clinical practice holds promise for improving functional capacity, quality of life, and long-term outcomes in selected patient populations. Continued research and clinical vigilance are essential to maximize benefits while minimizing risks, ensuring these advances translate into meaningful clinical gains for patients with heart failure and cardiomyopathies.